| Name | Title | Contact Details |
|---|
As a leading DSO, Heartland Dental provides supported dentists, hygienists, and non-clinical team members with world-class non-clinical administrative support to help them achieve sustainable professional and personal growth. What started from the entrepreneurial spirit of Rick Workman, DMD, with a single dental practice, has evolved into supporting over 2,700 dentists in over 1,700 dental offices across 38 states. Heartland Dental is not your typical Dental Support Organization. Its legacy of being built by a dentist, for dentists along with its doctor-led culture and business model enables supported doctors to be the leaders of their practice, working with their teams to focus on providing great dentistry while Heartland Dental focuses on providing support for the day-to-day non-clinical administrative workflow. You can discover more about Heartland Dental`s Doctor Difference by visiting www.heartland.com. Mission: To support doctors and their teams as they deliver the highest quality dental care and experiences to the communities they serve while providing exceptional careers and creating value for our stakeholders.
Inter Valley Health Plan Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Pomona, CA. To find more information about Inter Valley Health Plan Inc., please visit www.ivhp.com
Wellnet Healthcare is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
New Mexico Health Connections will be a consumer-oriented and operated health plan, governed by experts in health care, consumer protection and medicine.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.